Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Gains from Investment Securities (2021 - 2025)

Krystal Biotech's Gains from Investment Securities history spans 5 years, with the latest figure at -$12.1 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 299.21% year-over-year to -$12.1 million; the TTM value through Dec 2025 reached $1.8 million, down 70.57%, while the annual FY2025 figure was $1.8 million, 70.57% down from the prior year.
  • Gains from Investment Securities for Q4 2025 was -$12.1 million at Krystal Biotech, down from $9.6 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $9.6 million in Q3 2025 and bottomed at -$12.1 million in Q4 2025.
  • The 5-year median for Gains from Investment Securities is $400000.0 (2025), against an average of $674789.5.
  • The largest YoY upside for Gains from Investment Securities was 12743.75% in 2024 against a maximum downside of 1909.49% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at $4.4 million in 2021, then crashed by 122.43% to -$986000.0 in 2022, then surged by 95.13% to -$48000.0 in 2023, then surged by 12743.75% to $6.1 million in 2024, then plummeted by 299.21% to -$12.1 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Gains from Investment Securities are -$12.1 million (Q4 2025), $9.6 million (Q3 2025), and $3.9 million (Q2 2025).